CDXS
CODEXIS, INC.
NASDAQ · Healthcare · Biotechnology · US
$1.12
+3.24%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$1.11
From 52W high−60.88%
Volume119385.00
Market cap$122.10M
P/E (TTM)—
P/S (TTM)1.6x
Div yield—
Key dataNov 4, 2026
Open
$1.11
From 52W high
−60.88%
Volume
119385.00
Market cap
$122.10M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−6.8x
P/E (TTM)
—
RSI (14)
32.8
MomentumView details →
1D Return
+3.24%
YTD Return
−34.05%
SummaryUpdated Jun 1, 2026
Codexis, Inc. (NASDAQ:CDXS) is a biotechnology company founded in 2002 and headquartered in Redwood City, California. The company went public in 2010 and specializes in developing engineered enzymes and proteins through its proprietary CodeEvolver protein engineering platform. Codexis has evolved from a broad enzyme development company to focus primarily on pharmaceutical manufacturing applications, particularly in the emerging field of small interfering RNA (siRNA) therapeutics production through its ECO Synthesis platform.
Similar companies
Latest newsMore news →
Codexis announced that it will report its third-quarter 2026 financial results after market close on November 12, 2026.6d agoCodexis Inc. announced an agreement with an unnamed pioneering siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis Manufacturing Platform.37d ago